Mylod%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at

## Overview Mylot%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at is a brand name for **lidocaine**. It is a local anesthetic of the amide class. ## Primary Indications * Topical anesthesia for skin and mucous membranes (e.g., prior to minor surgical procedures, insertion of IV lines, or for pain relief). ## Adult Dosing * **Topical:** Varies significantly by product concentration and application site. Follow specific product labeling and indication. For example, 2% to 5% solutions/ointments are commonly used for topical anesthesia. * **Maximum:** Avoid systemic absorption; maximum dose depends on the specific formulation and application area. ## Pediatric Dosing * Safety and efficacy in pediatric patients are not well established for many topical formulations. Use with caution and follow specific product guidelines for age-appropriateness. Dosing should be individualized based on the area and extent of application. ## Dose Adjustments * **Renal Impairment:** No specific dose adjustment typically required for topical use, as systemic absorption is generally minimal. * **Hepatic Impairment:** No specific dose adjustment typically required for topical use. ## Contraindications * Hypersensitivity to lidocaine or other amide local anesthetics. * Certain topical formulations may have specific contraindications related to application site (e.g., broken skin, infected areas). ## Adverse Effects * **Local:** Transient stinging, burning, or redness at the application site. * **Systemic (with excessive absorption):** Dizziness, lightheadedness, tinnitus, circumoral numbness, nausea, vomiting, tremors, seizures, cardiovascular depression (bradycardia, hypotension, arrhythmias), respiratory depression, and cardiac arrest. ## Key Drug Interactions * **Class I Antiarrhythmics (e.g., tocainide, mexiletine):** Additive effects on cardiac function may occur with significant systemic absorption. * **Beta-Blockers and Cimetidine:** May decrease hepatic clearance of lidocaine, potentially increasing serum lidocaine levels with significant systemic absorption. ## Monitoring * Monitor for signs of local irritation or systemic toxicity, especially with large surface area application or prolonged use. ## Clinical Pearls * Lidocaine's onset of action is rapid, typically within minutes. * Duration of action varies with formulation and concentration. * Avoid application to large, denuded skin surfaces or mucous membranes to minimize systemic absorption. * Consider the potential for methemoglobinemia, particularly in infants, with certain benzocaine-containing formulations (though Mylot%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at is lidocaine, this is a general caution for topical anesthetics). *** *Disclaimer: This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and current clinical guidelines. Always verify the most up-to-date drug information before making clinical decisions.*